Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Cytopenia 1

Interventions

Cytarabine 13fludarabine phosphate 10Etoposide 8Methotrexate 7Cyclophosphamide 7Busulfan 7Idarubicin 6Daunorubicin 6tipifarnib 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 5Cyclosporine 5Antilymphocyte Serum 5Vorinostat 4Tacrolimus 4Radiotherapy 4Mitoxantrone 4Lenalidomide 4Epoetin Alfa 4Azacitidine 4sargramostim 3merphos 3epoetin beta 3Topotecan 3Thioguanine 3Methylprednisolone 3Granulocyte-Macrophage Colony-Stimulating Factor 3Dexamethasone 3Decitabine 3Biopsy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × cedazuridine × Classical hematology × Clear all
NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡